
Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

In a phase 3 trial, none of the patients receiving nirogacestat reached median progression-free survival, indicating that it may effectively reduce disease progression.

The finding indicates that a potential vaccine can trigger a permanent response in individuals living with HIV-1.

Food insecurity was associated with an increased risk of dementia, poorer memory function, and faster memory decline in older adults.

Peanut sublingual immunotherapy offers a practical treatment option for peanut-allergic toddlers, reducing symptoms in 80% of children.

In addition to growing rates of STIs, there is concern for antimicrobial resistance to STIs.

The investigators note that continued support during breast cancer treatment is necessary for patient comfort beyond diagnosis and the initial phases of treatment.

The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.

Regardless of which of these vaccines patients receive, as long as they receive them according to the prescribed schedules, they can protect themselves and their community against the COVID-19 virus.

Tune in to this episode of the Independent Rx Forum for a comprehensive overview of the National Community Pharmacists Association's legislative priorities, updates on critical pharmacy-related bills, and insights into the legislative process.

A change in recurrence-free survival was also observed, with an 89% rate at 24 months in patients who achieved a complete pathologic response.

TcdBFBD, derived from a toxin found in Clostridium difficile, was tested in mouse models that mimicked different subtypes of breast cancer.



Although social determinants of health (SDOH) have been a major barrier to access of preexposure prophylaxis for those who are at risk of HIV, commercial determinants of health pose a similar barrier.

Study results indicate that outcomes were worse among those who inject illicit drugs and Black patients living with HIV.


Heart failure is a major cause of morbidity and mortality for adults with congenital heart disease (CHD), with the highest risk being for those with complex CHD lesions.

Major barriers to care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) can include navigating therapeutics and the cost of medications.

In crafting a patient-centered regimen, the convergence of expertise from physicians and pharmacists, paired with the values and preferences of patients, becomes paramount.

The study authors reported that plans in the South had the highest rates of exclusive PAs for either emtricitabine/tenofovir disoproxil fumarate or emtricitabine/tenofovir alafenamide even if the plan covered both, from 2018 to 2020.

The study findings indicate that health care professionals significantly underreport symptoms compared to patients with breast cancer, with reported comorbidities varying.

Pharmacies have the potential to introduce testing services, promote public health campaigns, collaborate with anemia-led clinics, and get more prescribing rights to diagnose anemia.

In part 2 of this series, trauma-informed pharmacist Helen Sairany, PharmD, MBA, discusses the physical manifestations of burnout.

For pharmacists and pharmacy technicians, who work diligently to ensure our health and well-being, choosing the perfect holiday gift can be a thoughtful way to express gratitude and brighten their season.

Pediatric individuals that are higher risk for APS must be followed to better understand affects

The review comes after phase 3 trial results that indicate an improvement in overall survival and progression-free survival, reducing the risk of disease progression and death.

The designation allows expedited development of ADP101 as a treatment for food allergy in children ages 4 to 17 with confirmed allergy to 1 or more of the 15 foods in the drug product.

According to the investigators, Streptococcus pneumoniae and non-typeable Haemophilus influenzae are dominant pathogens of otitis media after birth.

The growth chart could be a fast and accessible resource to indicate lean muscle mass in children.